Abstract
Nitric oxide is multifunctional messenger molecule in the brain, playing important roles including in learning and memory and in regulating the expression of trophic factors that may be reduced with aging. Small molecules that mimic the biological activity of NO, NO mimetics, will bypass cholinergic receptor activation and are anticipated to provide multiple pathways of treating and circumventing dementia in Alzheimers disease. Activation of soluble guanylyl cyclase and cGMP formation in the brain represents one element of effective neuroprotective pathways mediated by NO. Substantial evidence suggests that NO mimetics may display cGMP-dependent and cGMP-independent activity and may operate via multiple biochemical signaling pathways, both to ensure the survival of neurons subjected to stress and also to provide cognition-enabling pathways to circumvent dementia. GT 1061 is an NO mimetic compound currently in clinical trials for Alzheimers. A survey of current research indicates that NO mimetics will provide a combined neuroprotective and cognition-enabling approach to anti-neurodegenerative therapy.
Keywords: cognition, dementia, nitric oxide, cgmp, nitrate, alzheimers, neurodegeneration, bdnf
Current Alzheimer Research
Title: Nitric Oxide Mimetic Molecules as Therapeutic Agents in Alzheimers Disease
Volume: 2 Issue: 2
Author(s): Gregory R.J. Thatcher, Brian M. Bennett and James N. Reynolds
Affiliation:
Keywords: cognition, dementia, nitric oxide, cgmp, nitrate, alzheimers, neurodegeneration, bdnf
Abstract: Nitric oxide is multifunctional messenger molecule in the brain, playing important roles including in learning and memory and in regulating the expression of trophic factors that may be reduced with aging. Small molecules that mimic the biological activity of NO, NO mimetics, will bypass cholinergic receptor activation and are anticipated to provide multiple pathways of treating and circumventing dementia in Alzheimers disease. Activation of soluble guanylyl cyclase and cGMP formation in the brain represents one element of effective neuroprotective pathways mediated by NO. Substantial evidence suggests that NO mimetics may display cGMP-dependent and cGMP-independent activity and may operate via multiple biochemical signaling pathways, both to ensure the survival of neurons subjected to stress and also to provide cognition-enabling pathways to circumvent dementia. GT 1061 is an NO mimetic compound currently in clinical trials for Alzheimers. A survey of current research indicates that NO mimetics will provide a combined neuroprotective and cognition-enabling approach to anti-neurodegenerative therapy.
Export Options
About this article
Cite this article as:
Thatcher R.J. Gregory, Bennett M. Brian and Reynolds N. James, Nitric Oxide Mimetic Molecules as Therapeutic Agents in Alzheimers Disease, Current Alzheimer Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567205053585945
DOI https://dx.doi.org/10.2174/1567205053585945 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
tPA in the Central Nervous System: Relations Between tPA and Cell Surface LRPs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Solvent-Free Synthesis of 4,5-Dihydropyrano[c]chromene Derivatives Over TiO<sub>2</sub> Nanoparticles as an Economical and Efficient Catalyst
Current Catalysis Oxidative Stress and Amyloid Beta Toxicity in Alzheimer’s Disease: Intervention in a Complex Relationship by Antioxidants
Current Medicinal Chemistry Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study
Current Pharmaceutical Design The Pivotal Role of Nitric Oxide: Effects on the Nervous and Immune Systems
Current Pharmaceutical Design Difference in Blood Pressure Measurements Between Arms: Methodological and Clinical Implications
Current Pharmaceutical Design Current Advancements in Aβ Luminescent Probes and Inhibitors of Aβ Aggregation
Current Alzheimer Research Carbon Nano Tubes: Novel Drug Delivery System in Amelioration of Alzheimer’s Disease
Combinatorial Chemistry & High Throughput Screening The Molecular Mechanism of <i>Scutellaria baicalensis</i> Georgi Stems and Leaves Flavonoids in Promoting Neurogenesis and Improving Memory Impairment by the PI3K-AKT-CREB Signaling Pathway in Rats
Combinatorial Chemistry & High Throughput Screening Memory Improvement with Docosahexaenoic Acid Study (MIDAS)-Brief Review
Current Alzheimer Research Exploring Structural Requirements of Imaging Agents Against Aβ Plaques in Alzheimer’s Disease: A QSAR Approach
Combinatorial Chemistry & High Throughput Screening Insights into Aβ Aggregation: A Molecular Dynamics Perspective
Current Topics in Medicinal Chemistry Dynamics of Nicotinic Acetylcholine Receptors and Receptor-Associated Proteins at the Vertebrate Neuromuscular Junction
Current Alzheimer Research Susceptibility Genes in Hypertension
Current Pharmaceutical Design Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes
Current Pharmaceutical Design Subclinical Hypothyroidism and Cognitive Dysfunction in the Elderly
Endocrine, Metabolic & Immune Disorders - Drug Targets Alpha-1-Antichymotrypsin: A Common Player for Type 2 Diabetes and Alzheimer's Disease
Current Diabetes Reviews Immune-Inflammatory Activation in Acute Coronary Syndromes: A Look into the Heart of Unstable Coronary Plaque
Current Cardiology Reviews Modifiable Midlife Risk Factors for Late-Life Cognitive Impairment and Dementia
Current Psychiatry Reviews Quantitative Ultrasound in Diagnosis of Metabolic Bone Diseases
Current Medical Imaging